Although SMARCA2 degraders would have the potential to be developed as single agents in the clinic to treat SMARCA4mut cancers, we have begun to address whether rational and ubiquitously active pharmacologic combinations exist for SMARCA2 degraders in SMARCA4mut cancers. The gene discussed is SMARCA2; the disease is cancer.